STUDY OF ENHANCED IMMUNOGENECITY OF B7-1 GENE TRANSFECTED HUMAN HELA CELL LINE

ＳＴＵＤＹＯＦＥＮＨＡＮＣＥＤＩＭＭＵＮＯＧＥＮＥＣＩＴＹＯＦＢ７１ＧＥＮＥＴＲＡＮＳＦＥＣＴＥＤＨＵＭＡＮＨＥＬＡＣＥＬＬＬＩＮＥＨｅＸｉ何曦ＱｉｎＨｕｉｌｉａｎ秦慧莲ＸｉａｎｇＲｏｎｇ向荣ＺｈａｎｇＹｕｅｊｉａｎ张跃建ＹｅＷｅｎｆｅｉ叶闻斐Ｈｅ...

Study of enhanced immunogenecity of B7-1 gene transfected human hela cell line

Although cervical carcinoma cells may express the human papillomavirus protein E6 and E7, they fail to induce an effective specific cytotoxic T lymphocyte response. Recent studies suggest that expression of CD-80 (B7-1) on tumor cells is effective to induce antitumor immune responses.^1,2 In our study, CD-80 gene was transfected into human Hela cell line with a CD-80 expression plasmid (B7-l*pcDNA3) by electroporation, then the immunogenecity of the modified Hela cell was tested in TLMC (tumor lymphocyte mixed culture) system. [³H]thymidine lymphocyte proliferation assays showed that the response of human peripheral blood lymphocytes (PBLS) to CD-80 positive Hela cells demonstrated a substantial increase in cell proliferation compared to the response to control cells. Cocultivation of allogeneic PBLs with CD-80 positive tumor cells for three days can induce an increased secretion of IL-2. Our results demonstrate an immunostimulatory effect of CD-80 expression on cervical cancer cells, which provides a basis for the development of a therapeutic tumor vaccine. This work was supposed by CMB (No. 96-635) This is one of papers of the special issue on gene therapy research (Chin J Cancer Res Vol. 9 No. 4 December, 1997).